ClinicalTrials.gg

Program

darleukin

Also written as “L19IL2”, “L19IL2 + L19TNF” and “L19IL2 +L19TNF”.

Its studies are mostly in Melanoma · Carcinoma, Basal Cell · Colorectal Neoplasms · Pancreatic Neoplasms · Carcinoma, Renal Cell, led by Philogen.

Furthest: phase 3, since Oct 11, 20169 company-led studies, 5 open or runningNext primary completion: Jul 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Philogen95 open or runningphase 3since Oct 11, 2016Jan 22, 2010Jul 2028phase 2 · NCT06284590

Also a collaborator on its studies: Merck and eudax-s-r-l.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 22, 2010First studies: 2 phase 2 studiesFirst studyNCT01055522, NCT01058538
  2. Sep 8, 2010Phase 1 study in Pancreatic NeoplasmsNCT01198522 · 28 enrolled · Germany, Italy
  3. Feb 24, 2014Phase 2 study in MelanomaNCT02076633 · 21 enrolled · Italy
  4. Oct 11, 2016Phase 3 study in MelanomaNCT02938299 · 214 enrolled · France, Germany, Italy and more
  5. Apr 17, 2020Phase 2 study in Carcinoma, Basal CellNCT04362722 · 40 planned · Germany, Poland, Switzerland
  6. Jan 26, 2024Phase 2 study in MelanomaNCT06284590 · 162 planned · United States, Germany, Italy
  7. Nov 7, 2025Phase 2 study in Carcinoma, Basal CellNCT07227350 · 180 planned · United States, Germany, Greece and more
  8. Apr 15, 2026Phase 1 study in Colorectal NeoplasmsNCT07566897 · 96 planned · Italy

Ahead

  1. Jul 2028Primary completion: phase 2 study in MelanomaNCT06284590
  2. Dec 2029Primary completion: phase 1 study in Colorectal NeoplasmsNCT07566897
  3. Feb 2031Primary completion: phase 2 study in Carcinoma, Basal CellNCT07227350

TargetBeta

IL2 →read by rule
“An immunoconjugate consisting of the recombinant form of the cytokine interleukin-2 (IL-2) ”NCIt, by rule

Other programs on IL2

ProgramCompanyFurthest phaseStudies
daromunrulePhilogenphase 36
Daxokafusp AlfaSanofiphase 22
SAR444336Sanofiphase 22
Anti-PD-1/IL-2 Fusion Protein TEV-56278Teva Pharmaceutical Industriesphase 12
IL-2 Mutein/Fc Fusion Protein HM16390ruleHanmi Pharmaceuticalphase 11
Autologous IL-2-expressing Anti-mesothelin CAR T-cells OPB-101ruleoutpace-bio-incphase 11

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07566897Colorectal Neoplasms · Italy1Not yet recruitingDec 202996
NCT07227350Carcinoma, Basal Cell · United States, Germany, Greece and more2RecruitingFeb 2031180
NCT06284590Melanoma · United States, Germany, Italy2RecruitingJul 2028162
NCT04362722Carcinoma, Basal Cell · Germany, Poland, Switzerland2RecruitingSep 202440
NCT02938299Melanoma · France, Germany, Italy and more3Active, not recruitingOct 2024214
NCT02076633Melanoma · Italy2CompletedMay 201521
NCT01198522Pancreatic Neoplasms · Germany, Italy1TerminatedNov 201428
NCT01058538Carcinoma, Renal Cell · Germany, Italy2CompletedApr 200833
NCT01055522Melanoma · Austria, Germany, Italy and more2TerminatedFeb 2013102

How it is read

Names in the registry

  • “L19IL2”, 4 entries
  • “L19IL2 + L19TNF”, 1 entry
  • “L19IL2 +L19TNF”, 1 entry
  • “L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine”, 1 entry
  • “L19IL2+L19TNF”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.